PR Newswire06.05.19
Conventus Orthopaedics Inc., a medical device company dedicated to revolutionizing fracture treatment, announced that Rick Epstein will join the company as its new CEO, effective immediately. Epstein will also serve on the company's Board of Directors. Rick brings more than 30 years of experience in executive leadership roles transforming medical device businesses to fast growing and valuable enterprises, including his most recent role as the CEO of OMNI Life Sciences Inc.
"Rick has a track record of accelerating businesses through a focus on customer needs, meaningful product introductions and commercial success," said Richard Mott, Chairman of the Board of Directors for Conventus. "We are excited to have Rick lead Conventus to its next chapter of growth as we strive to change the practice of medicine."
"I am excited to join the Conventus team and lead the company through portfolio expansion and commercial growth. The Conventus CAGE technology is an innovative platform that is already improving patient outcomes in upper extremity fracture care," stated Epstein. "Our unique 3-dimensional, intramedullary solution provides a platform for expansion of differentiated products that address significant clinical unmet needs and enhance treatment options."
"Rick has a track record of accelerating businesses through a focus on customer needs, meaningful product introductions and commercial success," said Richard Mott, Chairman of the Board of Directors for Conventus. "We are excited to have Rick lead Conventus to its next chapter of growth as we strive to change the practice of medicine."
"I am excited to join the Conventus team and lead the company through portfolio expansion and commercial growth. The Conventus CAGE technology is an innovative platform that is already improving patient outcomes in upper extremity fracture care," stated Epstein. "Our unique 3-dimensional, intramedullary solution provides a platform for expansion of differentiated products that address significant clinical unmet needs and enhance treatment options."